| Metric | FY 2026 | FY 2025 |
|---|---|---|
| Revenue | 450.8 | 829.4 |
| Profit before tax | -723.9 | 51.5 |
| Net income | -724.2 | -1.6 |
| EPS (diluted, $ a share) | $-5.11 | $-0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -45.6% |
|---|---|
| Operating margin | -156.9% |
10-K filed with the SEC, NASDAQ: ARWR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Arrowhead Pharmaceuticals, Inc.: key numbers
- Share price
- $44.21Close, Nov 16
- Market cap
- $6.25B
- Shares outstanding
- 141.37MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Arrowhead Pharmaceuticals, Inc.
All →Arrowhead Pharmaceuticals Financial Results
Arrowhead Pharmaceuticals reported financial results for its fiscal year ended September 30, 2026, highlighting the commercial launch of REDEMPLO for familial chylomicronemia syndrome (FCS). The company reported 950 cumulative prescriptions since launch and announced that the FDA granted plozasiran entry into the STAR pilot program for severe hypertriglyceridemia, qualifying it for a 6-month priority review.
- Term
- FY2026
“Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there is now a company that is beginning to translate promise into real patient outcomes and the potential for durable shareholder value growth.”
Christopher Anzalone, Ph.D., President and CEO
“I believe we approach 2027 with the strongest combination of near-term commercial opportunity and scientific capability in our history.”
Christopher Anzalone, Ph.D., President and CEO
Arrowhead Pharmaceuticals $400M Debt Financing with Sixth Street Lending Partners
Arrowhead Pharmaceuticals refinanced its existing senior secured term loans by entering into a new $400 million Amended and Restated Financing Agreement with Sixth Street. The new facility significantly lowers borrowing costs from a 15% fixed rate to SOFR plus 5.50%, extends the maturity to November 2031, and eliminates previous requirements to sweep commercial revenue or milestone payments for debt repayment.
- Value
- $400M
- Counterparty
- Sixth Street Lending Partners
- Term
- 5 years